Napredna pretraga

Pregled bibliografske jedinice broj: 714393

Genetic differences in cytochrome P450 enzymes and antidepressant treatment response


Hodgson, Karen; Tansey, Katherine; Dernovsek, Mojca Zvezdana; Hauser, Joanna; Henigsberg, Neven; Maier, Wolfgang; Mors, Ole; Placentino, Anna; Rietschel, Marcella; Souery, Daniel et al.
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response // Journal of psychopharmacology, 28 (2014), 2; 133-141 doi:10.1177/0269881113512041 (međunarodna recenzija, članak, znanstveni)


Naslov
Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

Autori
Hodgson, Karen ; Tansey, Katherine ; Dernovsek, Mojca Zvezdana ; Hauser, Joanna ; Henigsberg, Neven ; Maier, Wolfgang ; Mors, Ole ; Placentino, Anna ; Rietschel, Marcella ; Souery, Daniel ; Smith, Rebecca ; Craig, Ian W. ; Farmer, Anne E. ; Aitchison, Katherine J. ; Belsy, Sarah ; Davis, Oliver S. P. ; Uher, Rudolf ; McGuffin, Peter

Izvornik
Journal of psychopharmacology (0269-8811) 28 (2014), 2; 133-141

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Antidepressant; cytochrome P450 enzymes; depression; drug metabolism; pharmacogenetics

Sažetak
Antidepressant response varies between patients, possibly due to differences in the rate cytochrome P450 enzymes metabolise antidepressants into inactive compounds. Drug metabolism rates are influenced by common variants in the genes encoding these enzymes. However, it remains unclear whether treatment outcomes can be predicted by either CYP450 genotype or antidepressant serum concentration. In GENDEP (a pharmacogenetic study of depressed individuals treated with either escitalopram or nortriptyline), serum concentrations of antidepressants and their primary metabolite were measured after eight weeks treatment and variants in CYP2D6 and CYP2C19 were genotyped. Amongst patients taking escitalopram (n=223), the genotype CYP2C19 was significantly associated with escitalopram serum concentrations and desmethylescitalopram:escitalopram ratio. For those taking nortriptyline (n=161), the CYP2D6 genotype was significantly associated with nortriptyline and 10-hydroxynortriptyline serum concentrations and 10- hydroxynortriptyline:nortrip-tyline ratio. CYP450 genotypes conferring greater enzyme activity were linked to lower drug serum concentrations and higher metabolite:drug ratios. Nonetheless, no significant association was found between either CYP450 genotype or antidepressant serum concentration and treatment response. While there is a significant relationship between the CYP450 genotype and serum concentrations of escitalopram and nortriptyline, the genotypes are not predictive of differences in treatment response for either drug. Furthermore, differences in antidepressant serum concentrations are not associated with variability in treatment response.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

Napomena
Corrigendum - DOI: 10.1177/0269881115577574



POVEZANOST RADA


Projekt / tema
108-1081870-1880 - 1H-MRS promjene u predviđanju terapijskog odgovora, relapsa i povrata depresije (Neven Henigsberg, )

Ustanove
Medicinski fakultet, Zagreb

Autor s matičnim brojem:
Neven Henigsberg, (200094)

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Uključenost u ostale bibliografske baze podataka:


  • MEDLINE
  • PsychINFO


Citati